Atossa Therapeutics, Inc. (ATOS) earnings
ATOS earnings moved a median of -0.42% by the close. Quarterly and annual ATOS reports and results, each read against the price at its own news timestamp. Back to the ATOS overview →
21 measured ATOS earnings events.
Where these ATOS earnings landedvs 19 measured ATOS earnings reactions
| Middle 50% of ATOS earnings reactions | -4.37% to +1.64% |
|---|---|
| Median reaction (to close) | -0.42% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 ATOS earnings events with a measured close landed between -4.37% and +1.64%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | Press release | -0.30% | -0.42% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | -0.30% | -0.42% | |
| Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | +0.55% | +3.32% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +0.55% | +3.32% | |
| Form 10-K ATOSSA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | +1.16% | -9.25% | |
| Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Press release | -0.21% | -1.74% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -0.21% | -1.74% | |
| Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update | Press release | +0.41% | — | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | +0.41% | — | |
| Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | Press release | -2.03% | +2.30% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | -2.03% | +2.30% | |
| Form 10-K ATOSSA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -2.09% | -6.00% | |
| Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -3.70% | -7.41% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -0.31% | -6.25% | |
| Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.82% | +1.64% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | +0.82% | +1.64% | |
| Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.38% | +0.69% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +1.38% | +0.69% | |
| Form 10-K ATOSSA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -2.04% | -8.00% | |
| Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +3.22% | -2.74% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | +3.22% | -2.74% |
Keep exploring
More ATOS: analyst actions → · SEC filings → · ATOS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EKIMAS CORPORATION (ASNB) | 223 | 0.00% | 45% |
| OASMIA PHARMACEUTICALS AB AMERICAN DEPOSITARY SHARE (OASM) | 223 | 0.00% | 35% |
| FibroGen, Inc (FGEN) | 220 | -0.50% | 45% |
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.